Mylan Launches Generic Malarone Tablets
Generic firm Mylan has launched a version of GlaxoSmithKline’s malaria drug Malarone (atovaquone and proguanil HCl), the company said. The product treats uncomplicated malaria caused by Plasmodium falciparum.
Mylan said it will market the tablet in 62.5 mg/25 mg and 250 mg/100 mg strength respectively. For the 12 months ending March 31, Malarone tablets had U.S. sales of roughly $89.4 million, according to IMS Health, Mylan noted.
The generics firm also said it has 299 applications for generic drugs awaiting review by the FDA, representing $105.2 billion in annual brand sales, according to IMS Health. Among the applications, 41 represent potential first-to-file application opportunities, which could give Mylan marketing exclusivity on drugs representing $25.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2013. — Harry Morrison
Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.